Title: DEFIBROTIDE AND/OR OLIGODEOXYRIBONUCLEOTIDES FOR TREATING ANGIogenesis-DEPENDENT TUMORS

Oligotide and DF inhibits tube formation of ELC, but not of HMEC or HUVEC

(57) Abstract: The use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. The tumors which can be treated are preferably angiogenesis-dependent tumors, such as multiple myeloma or breast carcinoma.
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
Formulations with anti-angiogenesis-dependent tumour action

The subject of the present invention is a method for treating a tumor-affected mammalian by administering to said mammalian an effective amount of defibrotide and/or oligotide; in particular it relates to the use of oligotide and/or defibrotide for the treatment of angiogenesis-dependent tumors.

Background of the invention

Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastases (20). It is normally suppressed in the adult, where angiogenesis occurs transiently only during reproduction, development and wound healing. Beyond a critical volume, a tumor cannot expand further in the absence of neovascularization (12). To promote this, a tumor must acquire the angiogenic phenotype which is the result of the net balance between positive (pro-angiogenic) and negative (anti-angiogenic) regulators (16). However, tumors are highly heterogenous in vascular architecture, differentiation, and functional blood supply (24). These differences in size of avascular preangiogenic tumors may be due in part to the capacity of tumor cells to survive under differing degrees of hypoxia (18).

Evidence for the angiogenesis-dependingency of certain tumors, such as multiple myeloma, even non-solid leukemias and lymphomas (8) and (21), as well as breast (25), colorectal (7), gastric (26), prostate (9), cervix (19), hepatocellular (23), and non-small cell lung cancer (13) came from the observation that the
measure of the degree of angiogenesis, the microvessel density, is an independent prognostic factor for survival in the mentioned clinical entities (17). In a recent clinical study, again in breast carcinoma, it became clear that angiogenesis-related genes are important for clinical outcome, for example the vascular endothelial cell growth factor VEGF, the VEGF receptor FLT1, and metalloproteinase MMP9 (6).

**Definitions**

The term oligotide is herein used to identify any oligodeoxyribonucleotide having a molecular weight of 4000-10000 Dalton. Preferably it identifies any oligodeoxyribonucleotide having the following analytical parameters:

- molecular weight (mw): 4000-10000 Dalton,
- hyperchromicity (h): <10,
- A+T/C+G: 1.100-1.455,
- A+G/C+T: 0.800-1.160,
- specific rotation: +30°- +46.8°, preferably +30°- +46.2°.

The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. Preferably, when produced by extraction, it will be obtained in accordance with the method described in (1), (2), and (3) which are incorporated herein by reference. The oligotide is known to be endowed with a significant anti-ischemic activity.

The term defibrotide identifies a polydeoxyribonucleotide that is obtained by extraction from animal and/or vegetable tissues but which may also
be produced synthetically; the polydesoxyribo-nucleotide is normally used in the form of an alkali-metal salt, generally a sodium salt, and generally has a molecular weight of about 45-50 kDa (CAS Registry Number: 83712-60-1). Preferably, defibrotide presents the physical/chemical characteristics described in (4) and (5), which are incorporated herein by reference.

DESCRIPTION OF THE INVENTION

We have recently developed a model for an alternative pathway of tumor angiogenesis. In addition to the endothelial cell sprouting from pre-existing vessels, we suggest that blood borne endothelial cells might also give rise to the tumor vasculature. These endothelial-like cells (ELC) can transdifferentiate from tumor-associated dendritic cells under specific culture conditions (11). Briefly, monocytes are elutriated from leukapheresis products of healthy human blood donors and cultured in the presence of granulocyte-macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) to stimulate the differentiation of dendritic cells (DC). In addition, cells are treated with a cocktail specifically released by tumor cells (M-CSF, IL.6 and lactate, Gottfried et al., manuscript submitted) to promote the outgrowth of tumor-associated dendritic cells (TuDC).

These TuDC-ELC acquire the phenotype of endothelial cells (FactorVIII related Ag, vWF) while they lose monocytic (CD14) and dendritic cell markers (CD1a). Importantly, they do not express CD34, nor CD133 or CD146 which proves that they are real transdifferentiation products and no contaminants of either circulating endothelial progenitors (CD34, CD133) or mature circulating endothelial cells (CD146).
In addition, they are able to form tube-like structures in Matrigel™, an in vitro assay of angiogenesis.

The Matrigel™ assay is one of the most popular and widely used in vitro angiogenesis assays (22). Matrigel™ is a semisolid synthetic mixture of extracellular matrix proteins which simulate the matrix that physiologically exist beneath the endothelial cell wall of a blood vessel. When the cells of question are seeded onto this matrix in microscopic chamber slides, they are activated to form tubular structures in 3-7 days, but only in the case that they have an endothelial phenotype. Therefore, this assay is suitable to show the potential capacity of cells to give rise to a tumor vasculature.

Our data demonstrate that oligotide and/or defibrotide in clinical and subclinical concentrations can inhibit tube formation of transdifferentiating ELC (TuDC-ELC) in Matrigel™. TuDC-ELC and mature, differentiated endothelial cells, [human umbilical venous (HUVEC) or microvascular endothelial cells (HMEC)] as “stable” controls] were incubated in the presence or absence of oligotide or Defibrotide (10μg/mL each) for 7 days. Importantly, after a single addition of Defibrotide, HUVEC and HMEC are not affected in their tube formation potential, suggesting that Defibrotide and/or oligotide only target transdifferentiating endothelial cells (Figure 1A). However, when Defibrotide was added repeatedly, it could also block angiogenesis of mature, fully differentiated endothelial cells (see below).

By the help of a complimentary software from the NIH (Image J, http://rsb.info.nih.gov/ij/), we are able to quantify these effects, the total length of tubes and
the area of the photograph are assessed, the microvascular density (MVD) is then given in total length/area \([\text{pix-1}]\). DF significantly \((p=0.02, \text{TTEST})\) downregulates MVD of TuDC-ELC (Figure 1 B).

To support these data with an alternative angiogenesis assay the sprouting of rat aorta endothelial cells in Matrigel\textsuperscript{TM} was prevented by nearly 100\%, when DF was applied on a daily basis (Figure 2), suggesting that DF not only acts on transdifferentiating, but also on mature, fully differentiated endothelial cells.

The aortic ring assay investigates macrovascular endothelial cells. But often, the tumor vasculature consists of microvascular endothelial cells. Therefore, a third in vitro angiogenesis assay was performed on the basis of microvascular endothelial cells vascularizing through a layer of dermal fibroblasts after 9-11 days of culture. These vessel-like structures can subsequently be visualized by staining for CD31 and vWF.

As demonstrated in Figure 3 (A and B), DF can also block angiogenesis of human microvascular endothelial cells with a superiority for the daily application. Interestingly, concentrations around 10 \(\mu\text{g/mL}\) appear to be the most effective. A single application of DF could not significantly block angiogenesis.

Taken together, our data strongly suggest that defibrotide and/or oligotide can block angiogenesis of tumor-associated transdifferentiating endothelial cells and those that arise from already existing vascular cells.

It is subject to ongoing studies whether oligotide and defibrotide also inhibit angiogenesis in vivo. We are currently performing a dorsal skin chamber assay (14)
that investigates the effect of defibrotide in a highly vascularized human gastric carcinoma mouse model (Xenograft system). First data clearly show that the microvascular density (MVD) of DF-treated tumors is lower than that of control tumors. This set of experiments will be reproduced in due time.

The mechanism of action by which DF can block angiogenesis remains to be elucidated, but preliminary evidence from Western Blot analyses suggest a downregulating effect of DF on activated p70S6 kinase (p-p70S6), a mitogen-activated protein kinase.

Additional evidence for the impact of p70S6 kinase was obtained from another tube formation assay with HMEC incubated in the presence or absence of the p70S6 kinase inhibitor DRB.

There are also first clinical data available for patients (pts.) having received allogeneic stem cell transplantation (SCT): In a cohort of 17 defibrotide-treated pts a striking decline in serum VEGF levels has been seen, also suggesting that defibrotide might act through growth factor withdrawal for sprouting tumor endothelial cells.

Defibrotide and oligotide are strong candidates for a therapy of angiogenesis-dependent tumors and might be used alone or in combination with other anti-angiogenic agents, such as rapamycin (14). Interestingly, rapamycin has the negative side effect of pro-thrombotic activity (15) that could be attenuated by the simultaneous application of the anti-thrombotic and fibrinolytic defibrotide.

References

1. US5646127
2. US5646268
3. US6046172
4. US4985552
5. US5223609


CLAIMS

1. Use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton, for the manufacture of a pharmaceutical formulation for the treatment of angiogenesis-dependent tumor.

2. Use according to claim 1, characterized in that said oligodeoxyribonucleotides have the following analytical parameters: \( h < 10 \), \( A+T/C+G: 1.100-1.455 \), \( A+G/C+T: 0.800-1.160 \), specific rotation: \(+30^\circ - +46.8^\circ\).

3. Use according to claim 2, characterized in that the specific rotation is comprised between \(+30^\circ\) and \(+46.2^\circ\).

4. Use according to claim 1, characterized in that said oligodeoxyribonucleotides and/or defibrotide are obtained by extraction from animal and/or vegetable tissues, preferably from mammalian organs.

5. Use according to claim 1, characterized in that said oligodeoxyribonucleotides and/or defibrotide are obtained synthetically.

6. Use according to claim 1, characterized in that said angiogenesis-dependent tumor is multiple myeloma.

7. Use according to claim 1, characterized in that said angiogenesis-dependent tumor is breast carcinoma.

8. Use according to claim 1, characterized in that said formulation is administered to a mammalian.

9. Use according to claim 1, characterized in that said mammalian is a human.

10. Use according to claim 1, characterized in that said formulation is administered intravenously.
11. Use according to claim 1, characterized in that said formulation is an aqueous solution.

12. Use according to claim 1, characterized in that said formulation contains at least another active ingredient with anti-tumour action.

13. Use according to claim 12, characterized in that the other active ingredient with anti-tumour action is selected from rapamycin, paclitaxel, monocrotaline, BCNU, and/or cyclophosphamide.

14. Use according to claim 1, characterized in that said formulation contains customary excipients and/or adjuvants.
Oligotide and DF inhibits tube formation of ELC, but not of HMEC or HUVEC
DF inhibits tube formation, not transdifferentiation of TuDC-ELC
DF prevents EC sprouting in the aortic ring assay
FIG. 3A

DF prevents angiogenesis of human microvascular endothelial cells in the AngioKit™ assay

Microvascular Density (MVD) [pix^2] = Total length of vessels [pixel] / area [pixel]
FIG. 3B

DF prevents angiogenesis of human microvascular endothelial cells in the AngioKit™ assay

**p = 0.022**
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

INV. A61K31/711 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

**See patent family annex.**

**Date of the latest completion of the international search**

14 June 2006

**Date of mailing of the international search report**

04/08/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5018 Patentlaan 2 NL - 2280 HV RIjswijk
Tel (+31-70) 340-2940, Tx. 31 651 epo-nl, FAX (+31-70) 340-3016

Authorized officer

Albayrak, T
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 98/48843 A (BURCOGLU, ARSINUR) 5 November 1998 (1998-11-05) claims 1,17-23</td>
<td>1</td>
</tr>
<tr>
<td>A</td>
<td>EP 0 558 833 A (CRINOS INDUSTRIA FARMACOBIOLOGICA S.P.A) 8 September 1993 (1993-09-08) claims 1-30</td>
<td>1-14</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>DE 19740384 A1</td>
<td>11-03-1999</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7160998 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2259041 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1202750 A1</td>
</tr>
<tr>
<td>WO 2005023273 A</td>
<td>17-03-2005</td>
<td>AU 2004269896 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2537226 A1</td>
</tr>
<tr>
<td>EP 0558833 A</td>
<td>08-09-1993</td>
<td>AU 655087 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2968592 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BE 1008163 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9204931 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2083416 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 685298 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1073448 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2684675 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 92100527 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 103757 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IT 1252174 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5247083 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LU 88197 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX 9207137 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 101113 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6046172 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9208878 A</td>
</tr>
</tbody>
</table>